Hims & Hers Health (NYSE:HIMS) Announces Earnings Results

Hims & Hers Health (NYSE:HIMS) released its earnings results on Monday. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03, Briefing.com reports. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The business had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. During the same period last year, the business posted ($0.05) earnings per share. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. Hims & Hers Health updated its FY 2024 guidance to EPS and its Q2 2024 guidance to EPS.

Hims & Hers Health Stock Up 6.1 %

Shares of HIMS stock opened at $12.36 on Wednesday. Hims & Hers Health has a 12-month low of $5.65 and a 12-month high of $17.16. The business has a 50-day moving average price of $14.04 and a two-hundred day moving average price of $10.35. The firm has a market cap of $2.65 billion, a P/E ratio of -112.36 and a beta of 0.97.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HIMS. Jefferies Financial Group reiterated a “hold” rating and issued a $15.00 price target (down from $17.00) on shares of Hims & Hers Health in a research report on Tuesday, April 16th. Citigroup lifted their price target on Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Tuesday. Leerink Partnrs reiterated a “market perform” rating on shares of Hims & Hers Health in a research report on Monday, February 26th. Finally, Truist Financial lifted their price target on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.07.

Insider Activity

In other news, COO Melissa Baird sold 11,750 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $12.08, for a total value of $141,940.00. Following the completion of the sale, the chief operating officer now owns 538,932 shares of the company’s stock, valued at approximately $6,510,298.56. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $14.97, for a total value of $2,827,653.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Melissa Baird sold 11,750 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total value of $141,940.00. Following the completion of the sale, the chief operating officer now directly owns 538,932 shares of the company’s stock, valued at approximately $6,510,298.56. The disclosure for this sale can be found here. In the last quarter, insiders sold 736,191 shares of company stock valued at $9,733,700. Insiders own 31.63% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.